FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2962202317> ?p ?o ?g. }

• W2962202317 endingPage "5288" @default.
• W2962202317 startingPage "5274" @default.
• W2962202317 abstract "Abstract t(17;19)(q21‐q22;p13), responsible for TCF3‐HLF fusion, is a rare translocation in childhood B‐cell precursor acute lymphoblastic leukemia(BCP‐ALL). t(1;19)(q23;p13), producing TCF3‐PBX1 fusion, is a common translocation in childhood BCP‐ALL. Prognosis of t(17;19)‐ALL is extremely poor, while that of t(1;19)‐ALL has recently improved dramatically in intensified chemotherapy. In this study, TCF3‐HLF mRNA was detectable at a high level during induction therapy in a newly diagnosed t(17;19)‐ALL case, while TCF3‐PBX1 mRNA was undetectable at the end of induction therapy in most newly diagnosed t(1;19)‐ALL cases. Using 4 t(17;19)‐ALL and 16 t(1;19)‐ALL cell lines, drug response profiling was analyzed. t(17;19)‐ALL cell lines were found to be significantly more resistant to vincristine (VCR), daunorubicin (DNR), and prednisolone (Pred) than t(1;19)‐ALL cell lines. Sensitivities to three (Pred, VCR, and l ‐asparaginase [ l ‐Asp]), four (Pred, VCR, l ‐Asp, and DNR) and five (Pred, VCR, l ‐Asp, DNR, and cyclophosphamide) agents, widely used in induction therapy, were significantly poorer for t(17;19)‐ALL cell lines than for t(1;19)‐ALL cell lines. Consistent with poor responses to VCR and DNR, gene and protein expression levels of P‐glycoprotein (P‐gp) were higher in t(17;19)‐ALL cell lines than in t(1;19)‐ALL cell lines. Inhibitors for P‐gp sensitized P‐gp‐positive t(17;19)‐ALL cell lines to VCR and DNR. Knockout of P‐gp by CRISPRCas9 overcame resistance to VCR and DNR in the P‐gp‐positive t(17;19)‐ALL cell line. A combination of cyclosporine A with DNR prolonged survival of NSG mice inoculated with P‐gp‐positive t(17;19)‐ALL cell line. These findings indicate involvement of P‐gp in resistance to VCR and DNR in Pgp positive t(17;19)‐ALL cell lines. In all four t(17;19)‐ALL cell lines, RAS pathway mutation was detected. Furthermore, among 16 t(1;19)‐ALL cell lines, multiagent resistance was usually observed in the cell lines with RAS pathway mutation in comparison to those without it, suggesting at least a partial involvement of RAS pathway mutation in multiagent resistance of t(17;19)‐ALL." @default.
• W2962202317 created "2019-07-23" @default.
• W2962202317 creator A5001537454 @default.
• W2962202317 creator A5005186987 @default.
• W2962202317 creator A5006159126 @default.
• W2962202317 creator A5010053130 @default.
• W2962202317 creator A5010235104 @default.
• W2962202317 creator A5018769284 @default.
• W2962202317 creator A5023498778 @default.
• W2962202317 creator A5027219029 @default.
• W2962202317 creator A5029219416 @default.
• W2962202317 creator A5031545131 @default.
• W2962202317 creator A5032867036 @default.
• W2962202317 creator A5037062674 @default.
• W2962202317 creator A5038338410 @default.
• W2962202317 creator A5039385401 @default.
• W2962202317 creator A5041204580 @default.
• W2962202317 creator A5046158070 @default.
• W2962202317 creator A5048210816 @default.
• W2962202317 creator A5051110759 @default.
• W2962202317 creator A5055386220 @default.
• W2962202317 creator A5057138046 @default.
• W2962202317 creator A5061413614 @default.
• W2962202317 creator A5061728259 @default.
• W2962202317 creator A5064052373 @default.
• W2962202317 creator A5066756105 @default.
• W2962202317 creator A5075108063 @default.
• W2962202317 creator A5075507910 @default.
• W2962202317 creator A5078968582 @default.
• W2962202317 creator A5085013416 @default.
• W2962202317 creator A5085733466 @default.
• W2962202317 date "2019-07-15" @default.
• W2962202317 modified "2023-09-27" @default.
• W2962202317 title "Resistance of t(17;19)‐acute lymphoblastic leukemia cell lines to multiagents in induction therapy" @default.
• W2962202317 cites W117750355 @default.
• W2962202317 cites W1491375780 @default.
• W2962202317 cites W1576233656 @default.
• W2962202317 cites W1801876107 @default.
• W2962202317 cites W1863527347 @default.
• W2962202317 cites W1968174927 @default.
• W2962202317 cites W1970460848 @default.
• W2962202317 cites W1988579714 @default.
• W2962202317 cites W1996436910 @default.
• W2962202317 cites W1997936885 @default.
• W2962202317 cites W2012979952 @default.
• W2962202317 cites W2029150575 @default.
• W2962202317 cites W2036862498 @default.
• W2962202317 cites W2044131751 @default.
• W2962202317 cites W2050747338 @default.
• W2962202317 cites W2065764124 @default.
• W2962202317 cites W2076584338 @default.
• W2962202317 cites W2087105426 @default.
• W2962202317 cites W2087784887 @default.
• W2962202317 cites W2091710741 @default.
• W2962202317 cites W2103740216 @default.
• W2962202317 cites W2121587436 @default.
• W2962202317 cites W2125695832 @default.
• W2962202317 cites W2126394433 @default.
• W2962202317 cites W2140670979 @default.
• W2962202317 cites W2146473098 @default.
• W2962202317 cites W2170306203 @default.
• W2962202317 cites W2206058523 @default.
• W2962202317 cites W2215798291 @default.
• W2962202317 cites W2274867445 @default.
• W2962202317 cites W2393023456 @default.
• W2962202317 cites W2621252592 @default.
• W2962202317 cites W2751988461 @default.
• W2962202317 cites W2775612778 @default.
• W2962202317 cites W2794979171 @default.
• W2962202317 cites W4251482239 @default.
• W2962202317 cites W77471785 @default.
• W2962202317 doi "https://doi.org/10.1002/cam4.2356" @default.
• W2962202317 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6718581" @default.
• W2962202317 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31305009" @default.
• W2962202317 hasPublicationYear "2019" @default.
• W2962202317 type Work @default.
• W2962202317 sameAs 2962202317 @default.
• W2962202317 citedByCount "9" @default.
• W2962202317 countsByYear W29622023172020 @default.
• W2962202317 countsByYear W29622023172021 @default.
• W2962202317 countsByYear W29622023172022 @default.
• W2962202317 countsByYear W29622023172023 @default.
• W2962202317 crossrefType "journal-article" @default.
• W2962202317 hasAuthorship W2962202317A5001537454 @default.
• W2962202317 hasAuthorship W2962202317A5005186987 @default.
• W2962202317 hasAuthorship W2962202317A5006159126 @default.
• W2962202317 hasAuthorship W2962202317A5010053130 @default.
• W2962202317 hasAuthorship W2962202317A5010235104 @default.
• W2962202317 hasAuthorship W2962202317A5018769284 @default.
• W2962202317 hasAuthorship W2962202317A5023498778 @default.
• W2962202317 hasAuthorship W2962202317A5027219029 @default.
• W2962202317 hasAuthorship W2962202317A5029219416 @default.
• W2962202317 hasAuthorship W2962202317A5031545131 @default.
• W2962202317 hasAuthorship W2962202317A5032867036 @default.
• W2962202317 hasAuthorship W2962202317A5037062674 @default.
• W2962202317 hasAuthorship W2962202317A5038338410 @default.
• W2962202317 hasAuthorship W2962202317A5039385401 @default.
• W2962202317 hasAuthorship W2962202317A5041204580 @default.

• next